GLP-1 receptor agonists mimic a gut hormone that is released after eating. They stimulate insulin release, suppress glucagon, slow gastric emptying, and signal the brain to reduce appetite. Ozempic, Wegovy, and Rybelsus are all semaglutide — same molecule, different approvals. Mounjaro and Zepbound are tirzepatide, a dual GIP + GLP-1 agonist. These medications are approved for type 2 diabetes and obesity; they are not appropriate for type 1 diabetes. Cardiovascular benefit has been demonstrated in multiple large trials. Gastrointestinal side effects are common early on and typically improve with time.
How GLP-1 Medications Work: Ozempic, Wegovy, Mounjaro Explained
GLP-1 receptor agonists have become some of the most talked-about medications in modern medicine. Ozempic became a cultural shorthand for weight loss injections. Wegovy made headlines as the first drug to demonstrate substantial, sustained weight reduction in large clinical trials. Mounjaro and its weight-loss sibling Zepbound followed, with even more striking clinical results. The coverage is not exaggerated — these drugs represent a genuine shift in how medicine treats both type 2 diabetes and obesity.
But the conversation around them is often imprecise. Brand names get conflated. People confuse what each drug is approved for. The underlying biology — why they work at all — gets skipped entirely. This article explains GLP-1 receptor agonists from the mechanism up: what they are, how they differ from each other, who they are and are not for, and what the evidence actually says about their benefits and risks.
What Are GLP-1 Receptor Agonists?
GLP-1 stands for glucagon-like peptide-1. It is a hormone produced naturally by L-cells in the lining of the small intestine in response to eating. After a meal, GLP-1 is released into the bloodstream and acts on multiple organs simultaneously to coordinate the body's response to incoming nutrients.
In a healthy person, GLP-1 does several things at once. In the pancreas, it binds to GLP-1 receptors on beta cells and stimulates the release of insulin — but only when blood sugar is elevated, which is why the effect is called glucose-dependent. At the same time, it suppresses glucagon, a hormone released by alpha cells in the pancreas that signals the liver to release stored glucose. Blocking glucagon prevents the liver from pouring additional glucose into the bloodstream at exactly the moment it is least needed. Together, these two pancreatic effects lower blood sugar without the hypoglycemia risk associated with insulin — because if blood sugar is already low, the GLP-1 signal is weaker.
GLP-1 also slows gastric emptying — the rate at which food leaves the stomach and enters the small intestine. Slower gastric emptying means nutrients are absorbed more gradually, blunting the post-meal glucose spike. And GLP-1 acts on the brain — specifically on the hypothalamus and brainstem — to reduce appetite and increase feelings of satiety. You feel fuller sooner and stay full longer. This central appetite suppression is a major driver of weight loss with these medications.
The problem with natural GLP-1 is that it is broken down rapidly by an enzyme called DPP-4 (dipeptidyl peptidase-4), giving it a half-life of just one to two minutes in the bloodstream. GLP-1 receptor agonists are engineered molecules that mimic the action of GLP-1 but are resistant to DPP-4 degradation — giving them a much longer half-life, from hours to days to a full week depending on the agent. This sustained receptor activation is what makes them effective as once-weekly or once-daily medications.
Ozempic, Wegovy, and Rybelsus: All Semaglutide
Semaglutide is the active molecule in three separate brand-name products: Ozempic, Wegovy, and Rybelsus. Understanding what distinguishes them requires separating the molecule from the FDA approval and the delivery format.
Ozempic is a once-weekly subcutaneous injection of semaglutide. It is FDA-approved for the treatment of type 2 diabetes — specifically to improve blood sugar control in adults. Ozempic also has an FDA-approved indication to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is available in 0.5mg and 1mg pens, and a higher-strength 2mg pen.
Wegovy is also a once-weekly subcutaneous injection of semaglutide, but it is FDA-approved specifically for chronic weight management — for adults with obesity, or adults who are overweight and have at least one weight-related condition such as hypertension or high cholesterol. Wegovy is available at higher available strengths than Ozempic. The active ingredient is identical; the approval, the available strengths, and the prescribing criteria differ.
Rybelsus is the oral formulation of semaglutide — the first oral GLP-1 receptor agonist approved in the United States. It is FDA-approved for type 2 diabetes management. Rybelsus uses a special absorption technology (SNAC co-formulation) that allows semaglutide — normally broken down in the stomach — to survive the digestive environment and enter the bloodstream. It must be taken on an empty stomach with a small amount of water, and the patient must wait before eating or drinking anything else, to allow adequate absorption.
The practical consequence of this structure is significant for patients. A prescriber cannot simply write "semaglutide" and pick a brand — the choice of brand carries an approval, and that approval governs whether insurance will cover it. Patients with diabetes may find Ozempic covered but Wegovy denied, or vice versa depending on their plan. This has contributed to the phenomenon of people being prescribed Ozempic off-label for weight loss when Wegovy was unavailable or not covered — a practice that is medically similar but administratively fraught.
What Is Mounjaro / Zepbound? Tirzepatide Explained
Tirzepatide is a different molecule from semaglutide, and it works differently — though it overlaps in its GLP-1 mechanism. Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide receptor). GIP is a second incretin hormone, also released after eating, that stimulates insulin secretion. The two hormones work through separate receptor pathways, and activating both simultaneously appears to produce greater glycemic and weight effects than either alone.
Mounjaro (tirzepatide) received FDA approval in 2022 for the treatment of type 2 diabetes in adults. It is a once-weekly subcutaneous injection, available in a range of strengths from 2.5mg through 15mg pens. Clinical trials showed it produced greater reductions in HbA1c (a measure of long-term blood sugar control) than semaglutide in head-to-head comparisons.
Zepbound is tirzepatide approved in 2023 specifically for chronic weight management — the same molecule as Mounjaro, the same delivery method, but carrying the obesity/overweight indication. The SURMOUNT clinical trial program found that participants using tirzepatide lost substantially more weight than those in semaglutide trials — approximately 20–22% of body weight at the highest available strengths, compared to roughly 15% for semaglutide. Whether this superior efficacy reflects the dual GIP + GLP-1 mechanism or differences in how the molecule interacts with the receptors is still an active area of research.
The dual-receptor mechanism of tirzepatide may explain its advantages: GIP and GLP-1 receptors are expressed in different proportions across tissues, and simultaneous activation appears to produce synergistic effects on insulin secretion, glucagon suppression, fat metabolism, and appetite — beyond what activating either receptor alone achieves.
Other GLP-1 Medications
Semaglutide and tirzepatide are the newest and most widely prescribed GLP-1-class agents, but the class is older and broader. Several earlier GLP-1 receptor agonists remain in use:
Liraglutide (Victoza, Saxenda) was among the first long-acting GLP-1 receptor agonists approved in the United States. Victoza is approved for type 2 diabetes; Saxenda — the higher-strength version — is approved for obesity management. Liraglutide is a once-daily injection. The LEADER trial demonstrated that liraglutide reduced cardiovascular deaths in patients with type 2 diabetes and high cardiovascular risk.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes. It is available in 0.75mg and 1.5mg pens, with higher-strength options. The REWIND trial showed cardiovascular benefits in a broad population of people with type 2 diabetes, including those without prior cardiovascular events — a population not studied in earlier GLP-1 trials.
Exenatide (Byetta, Bydureon) was the first GLP-1 receptor agonist approved in the United States, in 2005. Byetta requires twice-daily injection. Bydureon is a once-weekly extended-release formulation. Exenatide is based on a peptide originally isolated from the saliva of the Gila monster lizard — a naturally occurring GLP-1-like molecule that proved resistant to DPP-4 degradation. Its use has declined as longer-acting, more convenient agents became available, but it remains approved and in use for type 2 diabetes.
| Drug (Brand) | Molecule | Frequency | Approval |
|---|---|---|---|
| Semaglutide (Ozempic / Wegovy / Rybelsus) | GLP-1 agonist | Weekly (injection) / Daily (oral) | T2D; Obesity |
| Tirzepatide (Mounjaro / Zepbound) | Dual GIP + GLP-1 agonist | Weekly injection | T2D; Obesity |
| Liraglutide (Victoza / Saxenda) | GLP-1 agonist | Daily injection | T2D; Obesity |
| Dulaglutide (Trulicity) | GLP-1 agonist | Weekly injection | T2D |
| Exenatide (Byetta / Bydureon) | GLP-1 agonist | Twice daily (Byetta) / Weekly (Bydureon) | T2D |
Common Side Effects: Why They Happen and What to Expect
The most common side effects of GLP-1 receptor agonists are gastrointestinal — nausea, vomiting, diarrhea, and constipation. These effects arise directly from the mechanism of the drug. Slowing gastric emptying means food sits in the stomach longer, which many people experience as nausea, particularly shortly after eating. The brain's appetite-suppression signals can also contribute to nausea, especially when starting or increasing to a higher available strength. The intestine, also rich in GLP-1 receptors, may respond with altered motility — sometimes diarrhea, sometimes constipation, depending on the individual.
Nausea and Vomiting
Nausea is the most reported side effect, affecting a substantial minority of patients — in clinical trials, often 15–40% report nausea at some point during treatment. For most people, nausea is worst in the initial weeks, improves as the body adjusts, and resolves for the majority of patients over the first few months. Eating smaller meals, avoiding high-fat foods, and not lying down immediately after eating can help. Severe or persistent vomiting that prevents adequate hydration warrants contact with your prescriber.
Diarrhea and Constipation
GI motility effects vary by individual. Some patients experience diarrhea early in treatment; others experience constipation, particularly as gastric emptying slows substantially. Both tend to improve over time. Staying well-hydrated and maintaining dietary fiber intake is generally helpful. If GI side effects are intolerable or persistent, your prescriber may adjust the approach — GI tolerability is one reason the prescribing process typically involves a slow escalation through lower available strengths before reaching higher ones.
⚠ GLP-1 receptor agonists carry a class warning about a potential risk of thyroid C-cell tumors based on animal studies. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This risk has not been confirmed in humans at approved strengths, but the contraindication stands. Discuss your personal and family medical history with your prescriber before starting a GLP-1.
Pancreatitis
Cases of acute pancreatitis have been reported with GLP-1 receptor agonists. The absolute risk appears low, and causality is difficult to establish since type 2 diabetes itself is a risk factor for pancreatitis. Current guidelines do not recommend routine pancreatic monitoring but advise that GLP-1s should be discontinued if pancreatitis is suspected. Symptoms — severe, persistent abdominal pain that radiates to the back — warrant prompt medical evaluation.
Who Are GLP-1 Medications For?
GLP-1 receptor agonists have approved indications in two main populations:
- Adults with type 2 diabetes who need improved blood sugar control, often as an add-on to metformin or other oral agents, or as a transition away from insulin for appropriate patients. GLP-1s can also be combined with SGLT-2 inhibitors like empagliflozin, another class with cardiovascular and kidney benefits. Compare diabetes medications to understand where GLP-1s fit in the treatment landscape.
- Adults with obesity (BMI ≥ 30) or adults who are overweight (BMI ≥ 27) with at least one weight-related health condition — such as hypertension, type 2 diabetes, or high cholesterol — who are candidates for the weight-management-approved formulations (Wegovy, Zepbound, Saxenda).
GLP-1 receptor agonists are not appropriate for type 1 diabetes. In type 1 diabetes, the pancreas cannot produce insulin at all — the beta cells have been destroyed. The glucose-dependent insulin stimulation of GLP-1s requires functioning beta cells to work. Using a GLP-1 agonist alone in type 1 would not provide adequate blood sugar control and could be dangerous. People with type 1 diabetes require insulin therapy.
GLP-1s are also not indicated for weight loss in people who are at a healthy weight, or as a substitute for treating the underlying conditions that accompany obesity. They are medical therapies for recognized metabolic diseases — not cosmetic interventions. The decision to start one involves clinical assessment, not just a request.
GLP-1s and Heart Health
One of the most significant scientific developments in the GLP-1 story is the evidence for cardiovascular benefit. Early concern in diabetes drug approvals — following the rosiglitazone controversy — led the FDA to require cardiovascular outcomes trials for new diabetes medications. The GLP-1 class produced results that went far beyond simply proving they were safe for the heart.
LEADER Trial (Liraglutide)
The LEADER trial enrolled over 9,000 patients with type 2 diabetes and high cardiovascular risk and followed them for a median of 3.8 years. It found that liraglutide significantly reduced the primary composite endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke — a 13% relative risk reduction. Cardiovascular death was specifically reduced. This was the first evidence that a GLP-1 receptor agonist could protect the heart beyond blood sugar control alone.
SUSTAIN-6 Trial (Semaglutide)
The SUSTAIN-6 trial found that weekly semaglutide reduced the rate of major adverse cardiovascular events in people with type 2 diabetes — particularly driven by a reduction in non-fatal stroke. This was consistent with the LEADER finding and extended the cardiovascular benefit class signal to semaglutide specifically.
SELECT Trial (Semaglutide in Obesity)
Published in 2023, the SELECT trial was landmark because it enrolled people with obesity and established cardiovascular disease who did not have diabetes. Over approximately five years, semaglutide reduced the rate of major cardiovascular events by 20% compared to placebo. This demonstrated that the cardiovascular benefit was not simply a downstream effect of better blood sugar control — it extended to people without diabetes, suggesting the drug's mechanism has direct or indirect cardiovascular protective effects beyond glycemic management.
SURPASS-CVOT Trial (Tirzepatide)
Cardiovascular outcomes data for tirzepatide from the SURPASS-CVOT program confirmed that tirzepatide did not increase cardiovascular risk in people with type 2 diabetes, and data on cardiovascular benefit in people with obesity are being evaluated in ongoing trials.
The cardiovascular findings have elevated GLP-1 receptor agonists from blood-sugar drugs to cardiometabolic therapies — a shift reflected in guidelines from major cardiology societies, which now recommend GLP-1 agonists for people with type 2 diabetes and established cardiovascular disease regardless of whether their glycemic control is already adequate.
Frequently Asked Questions
Why is there an Ozempic shortage?
The Ozempic shortage that began in 2022 and persisted through subsequent years was driven by a collision of rapidly expanding demand and constrained manufacturing capacity. Semaglutide requires a complex biological manufacturing process that cannot be scaled up in months. When Wegovy launched and demand for both products surged far beyond initial projections — amplified by social media attention and expanded clinical indications — Novo Nordisk's production capacity could not keep pace. The FDA placed semaglutide on its drug shortage list, which legally opened the door for compounding pharmacies to produce copies. That practice raised safety concerns and was later challenged by the FDA and Novo Nordisk as supply improved. The situation illustrated how drug manufacturing timelines (years to build new facilities) cannot rapidly accommodate sudden demand spikes.
Are GLP-1s safe long-term?
Major clinical trials — including SUSTAIN (semaglutide), LEADER (liraglutide), and SURPASS (tirzepatide) — have followed patients for years and found GLP-1 receptor agonists to be well-tolerated with favorable cardiovascular safety profiles. The SELECT trial followed participants for approximately five years. Long-term safety data extending beyond five years is still accumulating, particularly for newer agents. Potential long-term considerations under active study include effects on thyroid tissue (a class-level concern identified in rodent studies that has not been confirmed at clinically meaningful risk in humans), and effects on muscle mass during significant weight loss. Ongoing post-market surveillance continues to build the long-term safety picture. Talk to your prescriber about your individual risk-benefit balance.
Can you stop taking GLP-1 medications?
For most people, GLP-1 medications work while you are taking them — benefits typically reverse after stopping. Blood sugar control in type 2 diabetes and weight management benefits can diminish within weeks to months of discontinuation. Clinical studies of semaglutide for obesity have found that participants who stopped the medication regained a significant portion of lost weight within a year. This does not mean GLP-1s can never be stopped — people who achieve sustained lifestyle change and metabolic improvement may be candidates for stepping down therapy, in close consultation with their prescriber. But stopping abruptly without a clinical plan is generally not advisable, particularly for people using these medications for blood sugar management.
Do GLP-1s work for everyone?
GLP-1 receptor agonists produce meaningful results in the majority of patients, but there is significant individual variation. In clinical trials for weight loss, a minority of participants are non-responders or minimal responders — researchers are actively investigating which genetic and physiological factors predict response. Tolerability also matters: patients who experience persistent nausea or other side effects and discontinue early will not see the full metabolic benefit. For blood sugar management in type 2 diabetes, GLP-1s are generally effective but may need to be combined with other agents like metformin or empagliflozin depending on the degree of glucose control needed. Your prescriber can assess whether a GLP-1 is the right choice for your specific situation.
What's the difference between GLP-1 medications for diabetes vs. weight loss?
The core mechanism is the same — GLP-1 receptor agonism — but medications approved specifically for weight loss are generally studied and approved at higher available strengths than their diabetes counterparts, or carry a distinct FDA-approved indication. Semaglutide is the clearest example: Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management — they contain the same molecule but have different approved indications, different available strengths, and different prescribing criteria. Tirzepatide follows the same pattern: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for weight loss. This distinction matters practically for insurance coverage — payers may cover one and not the other — and for the clinical criteria your prescriber must document. See our full diabetes medication comparison for more on how these agents fit alongside other options.
Identify a pill, check drug interactions, or compare diabetes medications side by side.
Compare Diabetes Medications on PillID